transient receptor potential cation channel subfamily M member 2Genealiases: EREG1 · KNP3 · LTRPC2 · LTrpC-2 · NUDT9H · NUDT9L1
Q-omics provides the consensus-scored TRPM2 profile across patient tissues and cancer cell-line models. TRPM2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRPM2 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, TRPM2 RNA expression shows 14,836 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, and LIHC as cancer lineages where TRPM2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPM2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPM2 survival associations across molecular data types. TRPM2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPM2 RNA expression–survival associations across cancer types. High TRPM2 expression shows unfavorable associations in KIRC, UVM, BRCA, OV and COAD, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRPM2 RNA expression.
This table summarizes TRPM2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRPM2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPM2 shows higher tumor expression in KIRC, BLCA, STAD, HNSC, THCA and KIRP. The KIRC box plot shows higher TRPM2 RNA expression in tumor versus normal tissue (log2 FC = +2.095, t-test p < 0.001).
This table shows molecular features associated with TRPM2 in patient tissues and cancer cell lines. In patient samples, TRPM2 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPM2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
